new version V2017

antithrombotics

Abciximab - Apixaban - Bivalirudin - Coumadin - Dabigatran - Deltaparin - Dicoumarol - Edoxaban - Eptifibatide - Fondaparinux - Fraxiparin - Heparin - Hirudin - Idraparinux - LMWH - Reviparin - Rivaroxaban - Tirofiban - UFH - Wafarin - Warfarin - Ximelagatran      

TrialStudied treatmentControl treatmentpatientsROBResultNCT

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009apixabanplacebo Exploratory Negative NCT00313300
APPRAISE-1 (2.5 mg bid), 2009apixabanplaceboNegativeNCT00313300
APPRAISE 2, 2011apixabanplacebo Low risk of bias Negative NCT00831441
APPRAISE japan ongoing apixabanplacebo Exploratory - NCT00852397
argatroban
ARGAMI-2, 1998Argatrobanheparin -
aspirin
VA-pilotaspirinplaceboNegative
ALDUSA-pilotaspirinplaceboNegative
VA-main, 1983aspirinplaceboSuggesting
Canadian (Aspirin + sulfinpyrazone), 1985aspirin + sulfinpyrazoneplaceboNegative
Canadian (Aspirin vs PBO), 1985aspirinplacebo -
Théroux, 1988aspirinplaceboSuggesting
ATACS-pilot, 1990aspirincontrolNegative
RISC, 1990aspirinplaceboSuggesting
atopaxar
LANCELOT ACSatopaxarplacebo Exploratory -
J-LANCELOT, 2010atopaxarplacebo Exploratory -
bivalirudin
BAT (Bittl), 1995bivalirudinheparin Low risk of bias Suggesting
HERO, 1997bivalirudinheparin Exploratory Suggesting
PROTECT-TIMI 30, 2006bivalirudineptifibatide + heparin Exploratory - NCT00250471
ACUITY (biva alone vs hep+aGP2b3a), 2006bivalirudinheparin + GP2b3a inhibitorsSuggestingNCT00093158
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsNegativeNCT00093158
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsNegative
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007bivalirudinheparin + GP2b3a inhibitorsSuggesting
clopidogrel
CURE, 2001clopidogrel + aspirinaspirinSuggesting
CURE (PCI sub study), 2001clopidogrelplacebo Exploratory -
CURRENT OASIS 7 (clopidogrel), 2010clopidogrel high-dose regimenclopidogrel standard-dose Low risk of bias Negative NCT00335452
coumadin
ASPECT-2 (coumadin vs aspirin), 2002coumadinaspirinSuggesting
ASPECT-2 (coumadin+asp vs asp), 2002coumadincontrol (on top of aspirin)Suggesting
dalteparin
FRISC (long term), 1996dalteparinplacebo (on top of aspirin) Exploratory Suggesting
FRISC (short term), 1996dalteparinplacebo (on top of aspirin) Low risk of bias -
FRIC prolonged treatment phase (LWMH vs PBO), 1997dalteparinplacebo (on top of aspirin)Negative
FRIC (acute phase LMWH vs UFH), 1997dalteparinUFH (on top of aspirin) Exploratory Negative
dipyridamol
Prandoni, 1991aspirin + dipyridamolplaceboNegative
Efegatran
Klootwijk, 1999Efegatranheparin Exploratory -
enoxaparin
RESCUEenoxaparinunfractionated heparin - NCT00077818
ESSENCE, 1997enoxaparinUFH (on top of aspirin)Suggesting
TIMI 11 B (short term), 1998enoxaparinUFH (on top of aspirin)Suggesting
TIMI 11 B (long term), 1998enoxaparinUFH (on top of aspirin)Negative
EVET, 2005enoxaparintinzaparinSuggesting
SYNERGY, 2005enoxaparinUFH (on top of aspirin)Negative NCT00043784
INTERACT, 2006enoxaparinUFH (on top of aspirin)Suggesting
fondaparinux
PENTUA, 2004fondaparinuxenoxaparin -
OASIS 5, 2006fondaparinuxenoxaparin - NCT00139815
hirudin
HELVETICA (Serruys), 1995Hirudinheparin Low risk of bias -
TIMI 9B, 1996Hirudinheparin Risk of bias -
GUSTO IIB, 1996Hirudinheparin Risk of bias -
OASIS pilot, 1997Hirudinheparin Exploratory -
OASIS, 1997Hirudinheparin Risk of bias -
HIT-4, 1999Hirudinheparin Exploratory -
OASIS 2, 1999Hirudinheparin Low risk of bias -
inogatran
TRIM, 1997Inogatranheparin Exploratory -
nadroparin
FRAXIS (6days), 1998nadroparinUFH (on top of aspirin) Low risk of bias Negative
FRAXIS (14 days), 1998nadroparinUFH (on top of aspirin)Negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009otamixabanunfractionated heparin Exploratory SuggestingNCT00317395
prasugrel
TRITON-TIMI 38, 2007prasugrelclopidogrel Low risk of bias Suggesting NCT00097591
TRILOGY ACS (overall population), 2012prasugrelclopidogrel Low risk of bias NegativeNCT00699998
ACAPULCO ongoing prasugrelclopidogrel -
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011rivaroxaban 2.5mgplacebo Low risk of bias Suggesting NCT00809965
ATLAS ACS 2 - TIMI 51 (5mg), 2011rivaroxaban 5mgplaceboSuggesting NCT00809965
sulfinpyrazone
Canadian (sulfinpyrazone alone), 1985sulfinpyrazoneplacebo -
ticagrelor
DISPERSE-2 (90mg), 2007ticagrelorclopidogrel Exploratory Negative
PLATO, 2009ticagrelorclopidogrel Low risk of bias SuggestingNCT00391872
ticlopidine
Florida UAticlopidineplaceboNegative
STAI, 1990ticlopidinecontrolSuggesting
trapidil
ModenatrapidilplaceboSuggesting
triflusal
Plaza, 1993triflusalplaceboSuggesting
TIM, 2000triflusalaspirin -
UFH
Theroux (heparin+ASP vs ASP), 1988UFHcontrol (on top of aspirin)Suggesting
Theroux (heparin+aspirin vs PBO), 1988UFH + aspirinplaceboSuggesting
Theroux (heparin vs PBO), 1988UFHplaceboSuggesting
Cohen (ATACS pilot) (heparin vs asp), 1990UFH, warfarinaspirinNegative
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990UFH, warfarincontrol (on top of aspirin)Negative
RISC (heparin+aspirin vs ASP), 1990UFHcontrol (on top of aspirin)Negative
RISC (heparin vs PBO), 1990UFHplaceboNegative
RISC (ASP+ heparin vs PBO), 1990UFH + aspirinplaceboSuggesting
ATACS (Cohen), 1994UFH, warfarincontrol (on top of aspirin)Negative
Holdright, 1994UFHcontrol (on top of aspirin)Negative
Gurfinkel (UFH+aspririn vs aspirin), 1995UFHplacebo (on top of aspirin)Negative
vorapaxar
TRACER, 2011vorapaxarplacebo (on top standard therapy) Low risk of bias - NCT00527943
warfarin
ATACS (pilot study) warfarin vs aspirin, 1990warfarinaspirinNegative
ATACS (pilot study) (warfarin vs control), 1990warfarincontrol (on top of aspirin)Negative
ATACS, 1994warfarincontrol (on top of aspirin)Negative
CARS, 1997warfarincontrol (on top of aspirin)Negative
Williams, 1997warfarinplacebo (on top of aspirin)Negative
OASIS Pilot (phase 1), 1998warfarincontrol (on top of aspirin)Negative
OASIS Pilot (phase 2), 1998warfarincontrol (on top of aspirin)Negative
OASIS-2 Warfarin Substudy, 2001warfarincontrol (on top of aspirin)Negative
Huyhn, 2001warfarinplacebo (on top of aspirin)Negative
APRICOT-2, 2002warfarincontrol (on top of aspirin)Negative
CHAMP, 2002warfarincontrol (on top of aspirin)Negative
WARIS, 2002warfarincontrol (on top of aspirin)Suggesting
LoWASA, 2004warfarincontrol (on top of aspirin)Negative
Zibaeenezhad, 2004warfarincontrol (on top of aspirin)Negative
ximelagatran
ESTEEM, 2003ximelagatranplacebo Exploratory -

acute myocardial infarction

argatroban
ARGAMI-2, 1998Argatrobanheparin -
bivalirudin
HERO, 1997bivalirudinheparin Exploratory Suggesting
coumadin
ASPECT, 1994coumadinplaceboSuggesting
ASPECT-2 (coumadin alone), 2002coumadinaspirinSuggesting
ASPECT-2 (coumadin+ASA vs ASA), 2002coumadincontrol (on top of aspirin)Negative
dalteparin
FRAMI, 1997Dalteparinplacebo -
BIOMACS II, 1999Dalteparinplacebo -
ASSENT Plus, 2003DalteparinUFHNegative
enoxaparin
ASSENT 3, 2001EnoxaparinUFHSuggesting
HART II, 2001EnoxaparinUFHNegative
AMI-SK, 2002Enoxaparinplacebo -
Baird, 2002EnoxaparinUFHNegative
ENTIRE-TIMI 2, 2002EnoxaparinUFHSuggesting
ASSENT 3 Plus, 2003EnoxaparinUFHNegative
fondaparinux
MICHELANGELO OASIS-6, 2006fondaparinuxplacebo Low risk of bias SuggestingNCT00064428
hirudin
TIMI 9B, 1996Hirudinheparin Risk of bias -
HIT-4, 1999Hirudinheparin Exploratory -
reviparin
CREATE, 2005Reviparinplacebo -
UFH
ISIS-2 Pilot, 1987UFHno heparinNegative
ECSG, 1992UFHplaceboNegative
OSIRIS, 1992UFHplaceboNegative
DUCCS, 1994UFHno heparinNegative
warfarin
CARS (warafrin 3mg), 1997warfarincontrol (on top of aspirin)Suggesting
CARS (warfarin 1mg), 1997warfarincontrol (on top of aspirin)Negative
Williams, 1997warfarinplacebo (on top of aspirin)Suggesting
WARIS, 1999warfarincontrol (on top of aspirin) -
WARIS II (warfarin alone), 2002warfarinaspirinSuggesting
APRICOT-2, 2002warfarincontrol (on top of aspirin)Suggesting
CHAMP, 2002warfarincontrol (on top of aspirin)Negative
WARIS II (warfarin+ASA), 2002warfarincontrol (on top of aspirin)Suggesting
Zibaeenezhad, 2004warfarincontrol (on top of aspirin)Negative
LoWASA, 2004warfarincontrol (on top of aspirin) Risk of bias Suggesting

atrial fibrillation

apixaban
phase 2 apixabanapixabanwarfarin standard dose Exploratory - NCT00787150
AVERROES, 2011apixabanaspirinineligible for VKA Low risk of bias Suggesting NCT00496769
ARISTOTLE, 2011apixabanwarfarin standard dose Low risk of bias ConclusiveNCT00412984
aspirin
AFASAK (aspirin vs placebo), 1989aspirinplacebo Low risk of bias Negative
AFASAK (aspirin vs warfarin standard dose), 1989aspirinwarfarin standard dose Risk of bias Negative
SPAF (aspirin,warfarin ineligible arm), 1991aspirinplaceboineligible for VKA Low risk of bias Negative
SPAF (aspirin , warfarin eligible arm), 1991aspirinplacebo Low risk of bias Suggesting
EAFT, 1993aspirinplaceboNegative
SPAF II (aspirin vs warfarin standard dose, age<75), 1994aspirinwarfarin standard dose Risk of bias Negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994aspirinwarfarin standard dose Risk of bias Negative
AFASAK II (aspirin vs warfarin low dose), 1998aspirinwarfarin low dose Risk of bias Negative
AFASAK II (aspirin vs warfarin standard dose), 1998aspirinwarfarin standard dose Risk of bias Negative
LASAF(aspirin vs no treatment), 1999aspirincontrol -
PATAF (vs coumadin low dose), 1999aspirincoumadin low dose Risk of bias Negative
PATAF (vs coumadin standard dose), 1999aspirincoumadin standard dose Risk of bias Negative
FFAACS , 2001aspirinplacebo (on top fluidione)Negative
BAFTA (aspirin vs warfarin standard dose) ongoing aspirinwarfarin standard dose -
clopidogrel
ACTIVE W, 2006aspirin + clopidogrelanticoagulant Risk of bias Suggesting NCT00243178
ACTIVE A, 2009aspirin + clopidogrelaspirin Low risk of bias Suggesting NCT00249873
coumadin
PATAF (coumadin low dose vs coumadin standard dose), 1999coumadin low dosecoumadin standard dose Risk of bias Negative
dabigatran
RE-LY 150mg (2nd prevention subgroup) dabigatran 150mgwarfarin Exploratory Suggesting
phase 2 dabigatrandabigatranwarfarin standard dose Exploratory - NCT01136408
PETRO (150mg), 2007dabigatran 150mgwarfarin standard dose Exploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard dose Risk of bias Suggesting NCT00262600
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard dose Risk of bias SuggestingNCT00262600
RE-LY 110mg (2nd prevention subgroup) , 2010dabigatran 100mgwarfarin Exploratory Suggesting
edoxaban
Weitz (edoxaban phase 2)edoxabanwarfarin standard dose Exploratory - NCT00504556
phase 2 edoxabanedoxabanwarfarin standard dose Exploratory - NCT00806624
ENGAGE-AF TIMI 48 High dose, 2013edoxaban high dosewarfarin standard dose Low risk of bias Suggesting NCT00781391
idraparinux
AMADEUS, 2008idraparinuxwarfarin standard dose Risk of bias Negative NCT00070655
idraparinux BOREALIS-AF ongoing idraparinuxwarfarin standard dose - NCT00580216
rivaroxaban
ROCKET-AF, 2010rivaroxabanwarfarin standard dose Low risk of bias Suggesting NCT00403767
ROCKET (2nd prevention subgroup) , 2011rivaroxabanwarfarinNegative
ROCKET J ongoing rivaroxabanwarfarin standard dose - NCT00494871
triflusal
NASPEAF (triflusal vs coumadin standard dose)), 2004triflusalcoumadin standard dose Risk of bias Negative
warfarin
AFASAK (warfarin standard dose vs control), 1989warfarin standard dosecontrol Risk of bias Suggesting
BAATAF (warfarin vs no treatment), 1990warfarin low dosecontrol Risk of bias Suggesting NCT00000517
SPAF (warfarin standard dose), 1991warfarin standard dosecontrol Risk of bias Suggesting
CAFA, 1991warfarin standard doseplacebo Low risk of bias Negative
SPINAF (warfarin vs placebo), 1992warfarin low doseplacebo Low risk of bias Negative
SPAF III, 1996warfarin + aspirinwarfarin standard dose Risk of bias -
AFASAK II (warfarin low dose vs warfarin standard dose), 1998warfarin low dosewarfarin standard dose Risk of bias Negative
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998warfarin + aspirinwarfarin standard dose Risk of bias Negative
MWNAF, 1998warfarin low dosewarfarin standard dose Risk of bias Negative
SAFT(warfarin low dose + aspirin vs no treatment), 2003warfarin low dose + aspirincontrol Risk of bias Negative
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard dose Risk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard dose Risk of bias Suggesting
SPORTIF V, 2005ximelagatranwarfarin standard dose Low risk of bias Suggesting

heart failure

aspirin
Barzizza (ASA), 1993aspirinplacebo Exploratory -
WASH (aspirin), 2004aspirinno treatmentNegative
clopidogrel
WATCH (clopidogrel vs aspirin) ongoing clopidogrelaspirin -
enoxaparin
THE-PRINCE (Kleber), 2003enoxaparinUFH -
rivaroxaban
COMMANDER HF, 2018rivaroxabanplaceboNegativeNCT01877915
warfarin
Barzizza (warfarin), 1993warfarinplacebo -
WASH (warfarin), 2004warfarinno treatmentNegative
HELAS (warfarin vs aspirin), 2006warfarinaspirin -
HELAS (warfarin vs placebo), 2006warfarinplacebo -
WATCH (warfarin vs aspirin), 2009warfarinaspirinSuggestingNCT00007683

percutaneous coronary intervention

abciximab
EPIC (with infusion), 1994Abciximabplacebo -
Simoons, 1994Abciximabplacebo -
EPILOG, 1997Abciximabplacebo -
CAPTURE, 1997Abciximabplacebo -
RAPPORT, 1998Abciximabplacebo -
EPISTENT, 1998Abciximabplacebo -
ERASER, 1999Abciximabplacebo -
ISAR-2, 2000Abciximabplacebo -
ADMIRAL, 2001Abciximabplacebo -
Kini, 2001Abciximabplacebo -
CADILLAC, 2002Abciximabplacebo -
Petronio, 2002Abciximabplacebo -
Tamburino, 2002Abciximabplacebo -
aspirin
Taylor (Perth), 1991aspirinplaceboNegative
M-HEART II (aspirin), 1995aspirinplaceboNegative
bivalirudin
ARMYDA BIVALVEbivalirudinUFH -
BAT (Bittl), 1995bivalirudinUFH Low risk of bias Suggesting
Kleiman, 2002bivalirudin + eptifibatideheparin + GP2b3a inhibitors Exploratory -
REPLACE-2, 2003bivalirudinheparin + GP2b3a inhibitors -
REPLACE-1, 2004bivalirudinUFH Exploratory Negative
ACUITY (Stone) (bivalirudin alone), 2006bivalirudinheparin + GP2b3a inhibitors Risk of bias - NCT00093158
HORIZONS-AMI (Stone), 2008bivalirudinheparin + GP2b3a inhibitors Risk of bias SuggestingNCT00433966
ISAR-REACT 3, 2008bivalirudinUFH Low risk of bias - NCT00262054
NAPLES (Tavano), 2009bivalirudinUFH plus tirofiban Risk of bias Suggesting
BRAVE-4 ongoing Prasugrel and BivalirudinClopidogrel and Heparin - NCT00976092
cangrelor
CHAMPION-PCI, 2009cangrelor up frontclopidogrel up front Low risk of bias NegativeNCT00305162
CHAMPION-PLATFORM, 2009cangrelor up frontdelayed clopidogrelNegativeNCT00385138
CHAMPION PHOENIX, 2013cangrelorclopidogrel Low risk of bias SuggestingNCT01156571
cilostazol
Kunishima, 1997cilostazolaspirinNegative
Sekiya, 1998cilostazol + aspirinaspirinNegative
Ochiai, 1999cilostazol + aspirinticlopidine + aspirinNegative
Park, 1999cilostazol + aspirinticlopidine + aspirinNegative
Yoon, 1999cilostazol + aspirinticlopidine + aspirinNegative
Kozuma, 2001cilostazol + aspirinticlopidine + aspirinNegative
Kamishirado, 2002cilostazol + aspirinticlopidine + aspirinNegative
clopidogrel
Müller, 2000clopidogrel + aspirinticlopidine + aspirinNegative
CLASSICS, 2000clopidogrel + aspirinticlopidine + aspirinNegative
TOPPS, 2001clopidogrel + aspirinticlopidine + aspirinNegative
Piamsomboon, 2001clopidogrel + aspirinticlopidine + aspirinNegative
GRAVITAS, 2011high-dose clopidogrelnormal-dose clopidogrel Risk of bias NegativeNCT00645918
dalteparin
Natarajan (without antiGp2b3a), 2003dalteparinUFH -
Natarajan (+ antiGp2b3a), 2003dalteparinUFH + anti Gp2b3a -
dipyridamol
Schwartz (Toronto), 1988aspirin + dipyridamolplaceboSuggesting
Mayo-PTCA, 1989aspirin + dipyridamolplaceboNegative
Nye (Dunedin), 1990aspirin + dipyridamolplaceboNegative
White (aspirin+dipiridamol), 1991aspirin + dipyridamolplaceboNegative
elinogrel
INNOVATE PCIelinogrelclopidogrel - NCT00751231
enoxaparin
Rabah, 1999enoxaparinUFH Exploratory Negative
Dudek, 2000enoxaparinUFHNegative
Dudek b (enox alone), 2000enoxaparinUFH -
Galeote, 2001enoxaparinUFHNegative
Drozd, 2001enoxaparinUFHNegative
Dubek b (+abciximal), 2001enoxaparin+abciximabUFH -
CRUISE, 2003enoxaparinUFH Exploratory Negative
STEEPLE, 2006enoxaparinUFH Risk of bias - NCT00077844
ATOLL, 2010enoxaparinUFH Risk of bias -
STREAM ongoing enoxaparinunfractionated heparin - NCT00882635
eptifibatide
IMPACT (4h), 1995Eptifibatideplacebo -
Harrington, 1995Eptifibatideplacebo -
IMPACT-II (0.5µg), 1997Eptifibatideplacebo -
ESPRIT, 2000Eptifibatideplacebo -
fondaparinux
SWITCH III ongoing fondaparinuxunfractionated heparin or bivalirudin - NCT00464087
prasugrel
JUMBO-TIMI 26, 2005prasugrelclopidogrel Exploratory Negative
TRITOM TIMI 38 (PCI subgroup), 2009prasugrelclopidogrel -
TRIGGER-PCI ongoing prasugrelClopidogrel - NCT00910299
reviparin
REDUCE, 1996reviparinUFH Low risk of bias Suggesting
sulotroban
M-HEART II (sulotroban), 1995sulotrobanplacebo -
ticlopidine
TACT, 1990ticlopidineplaceboNegative
White (ticlopidine), 1991ticlopidineplacebo -
Hall, 1996ticlopidine + aspirinaspirinNegative
ISAR, 1996ticlopidine + aspirincoumadin + aspirinSuggesting
STARS (vs aspirin), 1998ticlopidine + aspirinaspirinSuggesting
FANTASTIC, 1998ticlopidine + aspirincoumadin + aspirinNegative
MATTIS, 1998ticlopidine + aspirincoumadin + aspirinNegative
STARS (vs coumadin+asp), 1998ticlopidine + aspirincoumadin + aspirinSuggesting
Foussas, 2000ticlopidine + aspirincoumadin + aspirinSuggesting
tirofiban
Kereiakis, 1996Tirofibanplacebo -
RESTORE, 1997Tirofibanplacebo -

peripheral vascular diseases

acenocoumarol
APIC, 1989acenocoumarolplacebo -
aspirin
Lassila R, 1991aspirincontrôle -
BOA, 2000aspirin -
CLIPS, 2007aspirinplacebo Low risk of bias Suggesting
clopidogrel
AFFIRM ongoing clopidogrel -
ticlopidine
Becquemin, 1997ticlopidinecontrôle -
UFH
Tesi, 1989HNFplacebo -
Antonicelli, 1999HNFplacebo -
warfarin
Sarac, 1998warfarincontrôle -
Johnson, 2002warfarincontrôle -

post acute coronary syndromes

dabigatran
REDEEM, 2009dabigatranplaceboNegativeNCT00621855

post myocardial infarction

dabigatran
REDEEM, 2009dabigatranplaceboNegativeNCT00621855

pulmonary embolism

apixaban
AMPLIFY-EXT 2.5mg, 2012apixaban 2.5mgdiscontinuationSuggestingNCT00633893
AMPLIFY-EXT 5mg, 2012apixaban 5mgdiscontinuationSuggestingNCT00633893
AMPLIFY, 2013apixaban (without LMWH)LMWH/VKA Low risk of bias SuggestingNCT00643201
Certoparin
Certoparin-Study Group sub group, 1998Certoparinunfractionated heparin Exploratory Negative
dalteparin
Kuijer, 1995Dalteparinunfractionated heparinNegative
Meyer, 1995Dalteparinunfractionated heparinNegative
enoxaparin
PREPIC, 1998Enoxaparinunfractionated heparin Risk of bias Negative
Merli sub group, 2001Enoxaparinunfractionated heparin Exploratory Negative
fondaparinux
MATISSE PE, 2003fondaparinuxheparin Risk of bias Negative
idraparinux
VanGogh PE, 2007idraparinux (without heparin)heparin/VKA Risk of bias Negative NCT00062803
nadroparin
European multicentre study, 1991Nadroparinunfractionated heparin Risk of bias Negative
Prandoni sub-group, 1992Nadroparinunfractionated heparin Exploratory Negative
Thery, 1992Nadroparinunfractionated heparin Exploratory Negative
reviparin
COLOMBUS sub group, 1997Reviparinunfractionated heparin Exploratory Negative
rivaroxaban
Einstein-PE Evaluation, 2012rivaroxaban (without LMWH)LMWH/VKA Risk of bias - NCT00439777
tinzaparin
ACTSG (Hull) sub-group, 1992Tinzaparinunfractionated heparin Exploratory Negative
THESEE, 1997Tinzaparinunfractionated heparin Risk of bias Negative
Campbell, 1998Tinzaparinunfractionated heparinNegative

stable angina

aspirin
SAPAT, 1992aspirinplacebo Low risk of bias Suggesting
clopidogrel
ASCETclopidogrelaspirin Risk of bias NegativeNCT00222261
dipyridamol
Foulds, 1960dipyridamolplacebo Exploratory -
Zion, 1961dipyridamolplacebo Exploratory -
Dewar, 1961dipyridamolplacebo Exploratory -
Kinsella, 1962dipyridamolplacebo Exploratory -
Leiberman, 1964dipyridamolplacebo Exploratory -
Neumann, 1964dipyridamolplacebo Exploratory -
Atlanta (Sbar), 1967dipyridamolcontrol Exploratory Negative
Becker, 1967dipyridamolcontrol Exploratory Negative
Wirecki, 1967dipyridamolcontrol Exploratory Negative
Igloe, 1970dipyridamolplacebo Exploratory -
ticlopidine
Berglund, 1985ticlopidineplacebo Exploratory Negative

stent

cilostazol
Kunishima, 1997cilostazolaspirinNegative
Sekiya, 1998cilostazol + aspirinaspirinNegative
Ochiai, 1999cilostazol + aspirinticlopidine + aspirinNegative
Park, 1999cilostazol + aspirinticlopidine + aspirinNegative
Yoon, 1999cilostazol + aspirinticlopidine + aspirinNegative
Kozuma, 2001cilostazol + aspirinticlopidine + aspirinNegative
Kamishirado, 2002cilostazol + aspirinticlopidine + aspirinNegative
clopidogrel
Müller, 2000clopidogrel + aspirinticlopidine + aspirinNegative
CLASSICS, 2000clopidogrel + aspirinticlopidine + aspirinNegative
TOPPS, 2001clopidogrel + aspirinticlopidine + aspirinNegative
Piamsomboon, 2001clopidogrel + aspirinticlopidine + aspirinNegative
REAL-LATE, ZEST-LATE, 2010clopidogrel+aspirinaspirinNegativeNCT00484926
GRAVITAS, 2011high-dose clopidogrelnormal-dose clopidogrel Risk of bias NegativeNCT00645918
ticlopidine
Hall, 1996ticlopidine + aspirinaspirinNegative
ISAR, 1996ticlopidine + aspirincoumadin + aspirinSuggesting
STARS (vs aspirin), 1998ticlopidine + aspirinaspirinSuggesting
FANTASTIC, 1998ticlopidine + aspirincoumadin + aspirinNegative
MATTIS, 1998ticlopidine + aspirincoumadin + aspirinNegative
STARS (vs coumadin+asp), 1998ticlopidine + aspirincoumadin + aspirinSuggesting
Foussas, 2000ticlopidine + aspirincoumadin + aspirinSuggesting

superficial thrombophlebitis

candesartan
Andreozzi (200 vs 100), 1996desmin 200desmin 100 -
Andreozzi (desmin SC vs 100), 1996desmin SCdesmin 100 -
coumadin
Belcaro (coumadin vs low dose hep), 1999coumadinlow dose heparin -
defibrotide
Belcaro, 1990defibrotidelow dose heparin -
Diclofenac
Nocker (diclofenac), 1991Diclofenacplacebo -
enoxaparin
Stenox (enoxaparin 40mg), 2003enoxaparinplacebo -
STENOX (enoxaparin 1.5mg/hg), 2003enoxaparinplacebo -
fondaparinux
CALISTO, 2010fondaparinuxplacebo Low risk of bias SuggestingNCT00443053
heparin
Belcaro (hep vs no hep), 1989heparinno treatment -
Belcaro (hep vs defibrotide), 1990heparin -
Marchiori, 2002heparinlow dose UFH -
Katzenschlager, 2003liposomal heparin-spraygelenoxaparin -
Gorski, 2005heparin spraygelclexane -
nadroparin
Titon (nadroparin 0.6ml vs naproxen), 1994nadroparinnaproxene -
Titon (nadroparin 61.5 IU anti-Xa/kg vs naproxen), 1994nadroparinnaproxene -
Vesalio, 2005nadroparin fixed-dosenadroparin weight-adjusted -
Nimesulide
Ferrari, 1992Nimesulidediclofenac -
UFH
Belcaro (prophylactic UFH vs no), 1999Prophylactic UFHno treatment -

thrombosis prevention

acenocoumarol
van Geloven, 1977Acenocoumarolunfractionated heparin -
Hamulyak, 1994AcenocoumarolNadroparinNegative
Samama, 2001AcenocoumarolReviparinNegative
apixaban
APROPOS 2.5mg, 2007apixabanenoxaparin (US regimen)knee surgery Exploratory NegativeNCT00097357
ADVANCE 3, 2010apixabanenoxaparinhip surgery Low risk of bias SuggestingNCT00423319
ADVANCE 2, 2010apixabanenoxaparin (europe regimen)knee surgery Low risk of bias SuggestingNCT00452530
ADOPT, 2011apixabanenoxaparinmedical patients Low risk of bias SuggestingNCT00457002
CV185-027 ongoing apixabanplacebo - NCT00320255
ardeparin
Godwin, 1993ardeparinunfractionated heparinabdominal surgery -
Levine, 1996ardeparinplaceboknee surgerySuggesting
Heit, 2000out of hospital Ardeparinstandard prophylaxisNegative
aspirin